Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Wall Street
Biotech
Kyverna CEO: 'We're in the next phase of medicine'
Kyverna's public proceeds will help finance operations into 2026.
Max Bayer
Feb 9, 2024 1:57pm
Alto aims for $101M IPO to pave neuro development climb
Jan 30, 2024 11:37am
Cargo, undeterred by market challenges, seeks $281M IPO
Nov 10, 2023 10:00am
Two biotechs go public while Apnimed bides its time
Oct 2, 2023 11:02am
Affini-T plans to go public in 2024
Jul 25, 2023 2:42pm
CERo to 60: Engineered T-cell biotech takes blank check route
Jun 5, 2023 11:09am